NASDAQ
ABCL

Abcellera Biologics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Abcellera Biologics Inc Stock Price

Vitals

Today's Low:
$5.13
Today's High:
$5.33
Open Price:
$5.33
52W Low:
$5.42
52W High:
$14.97
Prev. Close:
$5.36
Volume:
1853636

Company Statistics

Market Cap.:
$2.30 billion
Book Value:
4.299
Revenue TTM:
$485.42 million
Operating Margin TTM:
44.6%
Gross Profit TTM:
$311.11 million
Profit Margin:
32.66%
Return on Assets TTM:
9.47%
Return on Equity TTM:
14.03%

Company Profile

Abcellera Biologics Inc had its IPO on 2020-12-11 under the ticker symbol ABCL.

The company operates in the Healthcare sector and Biotechnology industry. Abcellera Biologics Inc has a staff strength of 495 employees.

Stock update

Shares of Abcellera Biologics Inc opened at $5.33 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $5.13 - $5.33, and closed at $5.14.

This is a -4.1% slip from the previous day's closing price.

A total volume of 1,853,636 shares were traded at the close of the day’s session.

In the last one week, shares of Abcellera Biologics Inc have slipped by -8.05%.

Abcellera Biologics Inc's Key Ratios

Abcellera Biologics Inc has a market cap of $2.30 billion, indicating a price to book ratio of 2.3182 and a price to sales ratio of 4.9327.

In the last 12-months Abcellera Biologics Inc’s revenue was $485.42 million with a gross profit of $311.11 million and an EBITDA of $244.35 million. The EBITDA ratio measures Abcellera Biologics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Abcellera Biologics Inc’s operating margin was 44.6% while its return on assets stood at 9.47% with a return of equity of 14.03%.

In Q4, Abcellera Biologics Inc’s quarterly earnings growth was a positive 45.9% while revenue growth was a negative 84.5%.

Abcellera Biologics Inc’s PE and PEG Ratio

Forward PE
27.4725
Trailing PE
16
PEG

Its diluted EPS in the last 12-months stands at $0.5 per share while it has a forward price to earnings multiple of 27.4725 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Abcellera Biologics Inc’s profitability.

Abcellera Biologics Inc stock is trading at a EV to sales ratio of 3.4915 and a EV to EBITDA ratio of 5.6146. Its price to sales ratio in the trailing 12-months stood at 4.9327.

Abcellera Biologics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.54 billion
Total Liabilities
$118.32 million
Operating Cash Flow
$-17063000.00
Capital Expenditure
$12.33 million
Dividend Payout Ratio
0%

Abcellera Biologics Inc ended 2024 with $1.54 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.54 billion while shareholder equity stood at $1.23 billion.

Abcellera Biologics Inc ended 2024 with $33.18 million in deferred long-term liabilities, $118.32 million in other current liabilities, 734365000.00 in common stock, $426.19 million in retained earnings and $47.81 million in goodwill. Its cash balance stood at $386.54 million and cash and short-term investments were $886.49 million. The company’s total short-term debt was $5,583,000 while long-term debt stood at $0.

Abcellera Biologics Inc’s total current assets stands at $1.03 billion while long-term investments were $72.52 million and short-term investments were $499.95 million. Its net receivables were $103.41 million compared to accounts payable of $14.83 million and inventory worth $1.53 million.

In 2024, Abcellera Biologics Inc's operating cash flow was $-17063000.00 while its capital expenditure stood at $12.33 million.

Comparatively, Abcellera Biologics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$5.14
52-Week High
$14.97
52-Week Low
$5.42
Analyst Target Price
$27.6

Abcellera Biologics Inc stock is currently trading at $5.14 per share. It touched a 52-week high of $14.97 and a 52-week low of $14.97. Analysts tracking the stock have a 12-month average target price of $27.6.

Its 50-day moving average was $6.38 and 200-day moving average was $7.98 The short ratio stood at 15.15 indicating a short percent outstanding of 0%.

Around 2864.1% of the company’s stock are held by insiders while 4651.5% are held by institutions.

Frequently Asked Questions About Abcellera Biologics Inc

The stock symbol (also called stock or share ticker) of Abcellera Biologics Inc is ABCL

The IPO of Abcellera Biologics Inc took place on 2020-12-11

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$64.5
-3.58
-5.26%
$18.08
-1.96
-9.78%
$498.35
-17.95
-3.48%
$1.76
-0.09
-4.86%
$370.7
3.48
+0.95%
$3.81
0.2
+5.54%
$11.34
1.78
+18.67%
$7.23
-0.09
-1.23%
Agrify Corp (AGFY)
$3.23
-0.14
-4.15%
$432.3
-5.5
-1.26%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Address

2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1